On the public citation graph
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
0 signed · 603 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6openalex-snapshot
Reporting results of cancer treatment
inferredcites →https://doi.org/10.1016/1074-7613(95)90125-6openalex-snapshot
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
inferredcites →https://doi.org/10.1016/s1470-2045(03)01280-4openalex-snapshot
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
inferredcites →https://doi.org/10.1038/35074122openalex-snapshot
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
inferredcites →https://doi.org/10.1038/ni1102-991openalex-snapshot
Cancer immunoediting: from immunosurveillance to tumor escape
inferredcites →https://doi.org/10.1038/ni846openalex-snapshot
CTLA-4–Ig regulates tryptophan catabolism in vivo
inferredcites →https://doi.org/10.1046/j.0300-9475.2001.01019.xopenalex-snapshot
Expression of CTLA‐4 by Human Monocytes
inferredcites →https://doi.org/10.1073/pnas.0403342101openalex-snapshot
Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease
inferredcites →https://doi.org/10.1073/pnas.0830997100openalex-snapshot
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
inferredcites →https://doi.org/10.1073/pnas.1533209100openalex-snapshot
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
inferredcites →https://doi.org/10.1084/jem.189.7.1157openalex-snapshot
Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8+ T Cells Independently of CD4+T Cell Help
inferredcites →https://doi.org/10.1084/jem.194.6.823openalex-snapshot
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
inferredcites →https://doi.org/10.1093/intimm/dxh140openalex-snapshot
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase
inferredcites →https://doi.org/10.1097/00002371-200101000-00010openalex-snapshot
Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2–Based Therapy
inferredcites →https://doi.org/10.1097/00002371-200409000-00004openalex-snapshot
Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy
inferredcites →https://doi.org/10.1097/00007890-199004000-00009openalex-snapshot
IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION
inferredcites →https://doi.org/10.1126/science.270.5238.985openalex-snapshot
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
inferredcites →https://doi.org/10.1126/science.271.5256.1734openalex-snapshot
Enhancement of Antitumor Immunity by CTLA-4 Blockade
inferredcites →https://doi.org/10.1146/annurev.immunol.19.1.565openalex-snapshot
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
inferredcites →https://doi.org/10.1172/jci106279openalex-snapshot
Metabolic properties of IgG subclasses in man
inferredcites →https://doi.org/10.1172/jci119110openalex-snapshot
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
inferredcites →https://doi.org/10.1172/jci21583openalex-snapshot
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
inferredcites →https://doi.org/10.1200/jco.1998.16.5.1743openalex-snapshot
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
inferredcites →https://doi.org/10.1200/jco.1999.17.3.791openalex-snapshot
Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance
inferredcites →https://doi.org/10.1200/jco.2000.18.1.158openalex-snapshot
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
inferredcites →https://doi.org/10.1200/jco.2001.19.15.3477openalex-snapshot
Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
inferredcites →https://doi.org/10.1200/jco.2005.01.128openalex-snapshot
Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
inferredcites →https://doi.org/10.1378/chest.122.1.171openalex-snapshot
Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism in the Cytotoxic T-Lymphocyte Antigen-4 Gene
inferredcites →https://doi.org/10.4049/jimmunol.171.11.6251openalex-snapshot
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4645176openalex-extracted
An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4628openalex-snapshot
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
inferred← citeshttps://doi.org/10.1002/9780470485408.ch31openalex-snapshot
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
inferred← citeshttps://doi.org/10.1002/9780470485408.ch5openalex-snapshot
Human Antibodies from Transgenic Mice
inferred← citeshttps://doi.org/10.1002/9780470571224.pse173openalex-snapshot
Safety Pharmacology: Similarities and Differences between Small Molecules and Novel Biopharmaceuticals
inferred← citeshttps://doi.org/10.1002/9781118345313.ch25openalex-snapshot
Co‐Administration of Co‐Stimulatory Moieties
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm065.pub2openalex-snapshot
Monoclonal Antibody and Targeted Toxin Therapy
inferred← citeshttps://doi.org/10.1002/9781394175635.ch14openalex-snapshot
Biomaterials‐Based Vaccinatio in Cancer Therapy
inferred← citeshttps://doi.org/10.1002/9783527619740.ch25openalex-snapshot
Antibodies in Phase I/II/III: Cancer Therapy
inferred← citeshttps://doi.org/10.1002/advs.202001308openalex-snapshot
Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.1002/cam4.2661openalex-snapshot
Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/cam4.371openalex-snapshot
CTLA ‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
inferred← citeshttps://doi.org/10.1002/cam4.6260openalex-snapshot
Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1002/cncr.21854openalex-snapshot
Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
inferred← citeshttps://doi.org/10.1002/cncr.22427openalex-snapshot
Chemotherapy for metastatic melanoma
inferred← citeshttps://doi.org/10.1002/cncr.22744openalex-snapshot
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma
inferred← citeshttps://doi.org/10.1002/cncr.23086openalex-snapshot
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
inferred← citeshttps://doi.org/10.1002/cncr.23805openalex-snapshot
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma
inferred← citeshttps://doi.org/10.1002/cncr.25639openalex-snapshot
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1002/eji.200838208openalex-snapshot
Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies
inferred← citeshttps://doi.org/10.1002/jcp.25019openalex-snapshot
Melanoma Treatments: Advances and Mechanisms
inferred← citeshttps://doi.org/10.1002/jcph.309openalex-snapshot
Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma
inferred← citeshttps://doi.org/10.1002/med.20110openalex-snapshot
Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines
inferred← citeshttps://doi.org/10.1002/med.21727openalex-snapshot
Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
inferred← citeshttps://doi.org/10.1002/pmic.200700062openalex-snapshot
Learning the drug target‐likeness of a protein
inferred← citeshttps://doi.org/10.1007/16833_2024_258openalex-snapshot
Immune Checkpoint Inhibitors: Novel Therapies and Targets
inferred← citeshttps://doi.org/10.1007/82_2010_49openalex-snapshot
Modulation of CTLA-4 and GITR for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-0-387-69118-3_1openalex-snapshot
Immune-Suppressive Mechanisms and Cancer: Understanding the Implications, Paradoxes, and Burning Questions
inferred← citeshttps://doi.org/10.1007/978-0-387-88495-0_15openalex-snapshot
Practical Management of Melanoma
inferred← citeshttps://doi.org/10.1007/978-1-4020-6087-8openalex-snapshot
General Principles of Tumor Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-1-4020-6087-8_16openalex-snapshot
Checkpoint Blockade and Combinatorial Immunotherapies
inferred← citeshttps://doi.org/10.1007/978-1-4020-6087-8_5openalex-snapshot
Immunomodulatory Molecules of the Immune System
inferred← citeshttps://doi.org/10.1007/978-1-4419-0170-5_3openalex-snapshot
Interleukin-21 and Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-1-4614-4732-0_4openalex-snapshot
Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts
inferred← citeshttps://doi.org/10.1007/978-1-4614-4732-0_8openalex-snapshot
Immune Co-signaling to Treat Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4899-8056-4_16openalex-snapshot
Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer
inferred← citeshttps://doi.org/10.1007/978-1-59745-332-5_21openalex-snapshot
Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/978-1-59745-337-0_20openalex-snapshot
Cytokine-Based Therapy for Cancer
inferred← citeshttps://doi.org/10.1007/978-1-60327-087-8_24openalex-snapshot
Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention
inferred← citeshttps://doi.org/10.1007/978-1-60327-087-8_48openalex-snapshot
Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer
inferred← citeshttps://doi.org/10.1007/978-1-60327-424-1_19openalex-snapshot
Drug Development in Cancer Medicine: Challenges for Targeted Approaches
inferred← citeshttps://doi.org/10.1007/978-1-60327-424-1_9openalex-snapshot
Targeted Therapy in Melanoma
inferred← citeshttps://doi.org/10.1007/978-1-60761-171-4_21openalex-snapshot
Pharmacogenetics and Pharmacogenomics I: Linking Diagnostic Classification to Therapeutic Decisions
inferred← citeshttps://doi.org/10.1007/978-1-60761-433-3_23openalex-snapshot
Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview
inferred← citeshttps://doi.org/10.1007/978-1-60761-980-2_1openalex-snapshot
Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancer
inferred← citeshttps://doi.org/10.1007/978-1-61779-407-0_14openalex-snapshot
Anti-CTLA-4 Monoclonal Antibodies
inferred← citeshttps://doi.org/10.1007/978-1-62703-062-5_16openalex-snapshot
Immunotherapy for Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/978-1-62703-727-3_1openalex-snapshot
Novel Insights/Translational Implication from the Emerging Biology of Melanoma
inferred← citeshttps://doi.org/10.1007/978-2-287-36008-4_12openalex-snapshot
CTLA-4 et Toll-like récepteurs: de nouvelles cibles en immunothérapie
inferred← citeshttps://doi.org/10.1007/978-3-030-05070-2_39openalex-snapshot
Checkpoint Inhibitors in the Treatment of Metastatic Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-15715-9_8openalex-snapshot
Modelling Cancer Dynamics Using Cellular Automata
inferred← citeshttps://doi.org/10.1007/978-3-030-18797-2_2openalex-snapshot
Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View
inferred← citeshttps://doi.org/10.1007/978-3-030-50287-4_1openalex-snapshot
Frontiers in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-50287-4_6openalex-snapshot
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.1007/978-3-031-15130-9_150openalex-snapshot
Immunotherapy for Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-319-05104-8_8openalex-snapshot
Dendritic Cell-Based Cancer Vaccines
inferred← citeshttps://doi.org/10.1007/978-3-319-32907-9_6openalex-snapshot
Developmental Therapeutics for Gynecologic Cancers: An Overview
inferred← citeshttps://doi.org/10.1007/978-3-319-46029-1_39-1openalex-snapshot
Checkpoint Inhibitors in the Treatment of Metastatic Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-319-62431-0_29openalex-snapshot
Strategies to Reduce Intratumoral Regulatory T Cells
inferred← citeshttps://doi.org/10.1007/978-3-319-63757-0_2openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-319-93530-0_7openalex-snapshot
Immune Checkpoint Inhibitors in Sarcoma
inferred← citeshttps://doi.org/10.1007/978-3-540-73259-4_4openalex-snapshot
Human Monoclonal Antibodies from Transgenic Mice
inferred← citeshttps://doi.org/10.1007/978-3-540-78814-0_4openalex-snapshot
Immunomodulation in Dermatology
inferred← citeshttps://doi.org/10.1007/978-3-662-44946-2_1openalex-snapshot
Frontiers in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-662-44946-2_6openalex-snapshot
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.1007/978-90-481-2289-9_10openalex-snapshot
Monoclonal antibody therapy
inferred← citeshttps://doi.org/10.1007/978-981-15-9038-2_2openalex-snapshot
Immunotherapy in Cancer: Immune Checkpoint Inhibitors; Changing Oncology Treatment Paradigm
inferred← citeshttps://doi.org/10.1007/s00105-008-1556-5openalex-snapshot
Experimentelle Tumortherapie beim malignen Melanom und ihre Rationale
inferred← citeshttps://doi.org/10.1007/s00262-006-0161-7openalex-snapshot
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
inferred← citeshttps://doi.org/10.1007/s00262-009-0811-7openalex-snapshot
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine
inferred← citeshttps://doi.org/10.1007/s00262-010-0844-yopenalex-snapshot
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
inferred← citeshttps://doi.org/10.1007/s00262-012-1293-6openalex-snapshot
The expression, function, and clinical relevance of B7 family members in cancer
inferred← citeshttps://doi.org/10.1007/s00262-013-1451-5openalex-snapshot
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
inferred← citeshttps://doi.org/10.1007/s00262-017-2073-0openalex-snapshot
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells
inferred← citeshttps://doi.org/10.1007/s00403-007-0771-8openalex-snapshot
First world meeting of interdisciplinary melanoma/skin cancer centers
inferred← citeshttps://doi.org/10.1007/s00761-010-1926-3openalex-snapshot
Systemische Therapie des metastasierten Melanoms
inferred← citeshttps://doi.org/10.1007/s10269-016-2633-5openalex-snapshot
Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non à petites cellules
inferred← citeshttps://doi.org/10.1007/s10637-009-9224-xopenalex-snapshot
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
inferred← citeshttps://doi.org/10.1007/s10637-009-9376-8openalex-snapshot
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
inferred← citeshttps://doi.org/10.1007/s11096-023-01678-7openalex-snapshot
Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11102-009-0193-zopenalex-snapshot
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
inferred← citeshttps://doi.org/10.1007/s11864-014-0305-5openalex-snapshot
Immune Checkpoint Inhibitors in NSCLC
inferred← citeshttps://doi.org/10.1007/s11912-008-0025-8openalex-snapshot
Head and neck cancer immunotherapy: Clinical evaluation
inferred← citeshttps://doi.org/10.1007/s12033-007-0020-6openalex-snapshot
Exploiting dendritic cells for active immunotherapy of cancer and chronic infections
inferred← citeshttps://doi.org/10.1007/s13277-015-3285-6openalex-snapshot
Immunotherapy for lung cancer: for whom the bell tolls?
inferred← citeshttps://doi.org/10.1007/s15035-010-0176-6openalex-snapshot
Tumorvakzinierung beim metastasierten Nierenzellkarzinom
inferred← citeshttps://doi.org/10.1007/s40259-016-0204-3openalex-snapshot
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/s40620-022-01537-0openalex-snapshot
Associations of health literacy with self-management behaviours and health outcomes in chronic kidney disease: a systematic review
inferred← citeshttps://doi.org/10.1016/b978-0-08-046884-6.00629-1openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-08-100601-6.02008-1openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-12-394296-8.00019-1openalex-snapshot
Antibodies to Stimulate Host Immunity
inferred← citeshttps://doi.org/10.1016/b978-0-12-801238-3.02008-0openalex-snapshot
Immunotoxicology of Biopharmaceutics☆
inferred← citeshttps://doi.org/10.1016/b978-0-12-802420-1.00011-9openalex-snapshot
Checkpoint Blockade Immunotherapy for Glioblastoma
inferred← citeshttps://doi.org/10.1016/b978-0-12-802585-7.00005-4openalex-snapshot
Costimulation in Lymphomas and Cancers
inferred← citeshttps://doi.org/10.1016/b978-0-12-820007-0.00024-6openalex-snapshot
Therapeutic antibody development—Remington chapter
inferred← citeshttps://doi.org/10.1016/b978-0-12-821909-6.00003-1openalex-snapshot
YY1 expression and PD-1 regulation in CD8 T lymphocytes
inferred← citeshttps://doi.org/10.1016/b978-0-12-822028-3.00014-5openalex-snapshot
Fcγ receptors—Master regulators of antibody therapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-822213-3.00004-8openalex-snapshot
Imaging mass cytometry in preclinical studies of lung cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-02752-6.50055-9openalex-snapshot
Management of Dysplastic Nevi and Melanomas
inferred← citeshttps://doi.org/10.1016/b978-0-323-06575-7.00043-2openalex-snapshot
Management of Dysplastic Nevi and Melanomas
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00030-xopenalex-snapshot
Therapeutic Antibodies and Immunologic Conjugates
inferred← citeshttps://doi.org/10.1016/b978-0-323-76097-3.00024-7openalex-snapshot
Endocrinopathies Associated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/b978-0-323-77684-4.00026-xopenalex-snapshot
Immunotherapy in gynecologic malignancies
inferred← citeshttps://doi.org/10.1016/b978-0-323-95488-4.50043-6openalex-snapshot
Immunotoxicology of Biopharmaceutics
inferred← citeshttps://doi.org/10.1016/b978-0-443-44181-3.00013-8openalex-snapshot
Transforming cancer treatment through immunotherapy innovations
inferred← citeshttps://doi.org/10.1016/b978-012372551-6/50076-6openalex-snapshot
Immunotherapy and Cancer Therapeutics: Why Partner?
inferred← citeshttps://doi.org/10.1016/b978-012372551-6/50078-xopenalex-snapshot
Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy
inferred← citeshttps://doi.org/10.1016/b978-1-4377-1788-4.00053-8openalex-snapshot
Adjuvant Therapy for Cutaneous Melanoma
inferred← citeshttps://doi.org/10.1016/b978-1-4377-1788-4.00057-5openalex-snapshot
Treatment of Disseminated Melanoma
inferred← citeshttps://doi.org/10.1016/b978-1-4557-4066-6.00042-1openalex-snapshot
Molecular Basis for Treating Cutaneous Melanoma
inferred← citeshttps://doi.org/10.1016/b978-1-4557-4066-6.00052-4openalex-snapshot
Cancer Immunotherapy with Vaccines and Checkpoint Blockade
inferred← citeshttps://doi.org/10.1016/b978-141603703-3.10055-xopenalex-snapshot
Monoclonal Antibody Therapy of Cancer
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2018.05.010openalex-snapshot
T Lymphocyte–Based Cancer Immunotherapeutics
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2022.03.003openalex-snapshot
Dendritic cell transfer for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.ajo.2007.02.035openalex-snapshot
Surveillance of the Eye and Vision in Clinical Trials of CP-675,206 for Metastatic Melanoma
inferred← citeshttps://doi.org/10.1016/j.anplas.2012.02.002openalex-snapshot
Toxicité dermatologique des nouvelles thérapies ciblées anticancéreuses utilisées en oncodermatologie
inferred← citeshttps://doi.org/10.1016/j.bbcan.2018.12.002openalex-snapshot
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.bbmt.2010.02.005openalex-snapshot
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction
inferred← citeshttps://doi.org/10.1016/j.beem.2019.101370openalex-snapshot
New insight in endocrine-related adverse events associated to immune checkpoint blockade
inferred← citeshttps://doi.org/10.1016/j.ccell.2019.09.006openalex-snapshot
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
inferred← citeshttps://doi.org/10.1016/j.cell.2021.09.020openalex-snapshot
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
inferred← citeshttps://doi.org/10.1016/j.clgc.2012.09.001openalex-snapshot
Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?
inferred← citeshttps://doi.org/10.1016/j.clim.2008.07.025openalex-snapshot
Invariant natural killer T cells and immunotherapy of cancer
inferred← citeshttps://doi.org/10.1016/j.clim.2010.09.011openalex-snapshot
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells
inferred← citeshttps://doi.org/10.1016/j.clindermatol.2008.09.012openalex-snapshot
Melanoma in the elderly patient: relevance of the aging immune system
inferred← citeshttps://doi.org/10.1016/j.clindermatol.2012.08.006openalex-snapshot
Immunomodulatory therapy for melanoma: Ipilimumab and beyond
inferred← citeshttps://doi.org/10.1016/j.cnsns.2016.08.020openalex-snapshot
Destruction of solid tumors by immune cells
inferred← citeshttps://doi.org/10.1016/j.coi.2006.01.011openalex-snapshot
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.coi.2008.06.004openalex-snapshot
Fully human antibodies from transgenic mouse and phage display platforms
inferred← citeshttps://doi.org/10.1016/j.coi.2014.01.002openalex-snapshot
Orchestrating immune check-point blockade for cancer immunotherapy in combinations
inferred← citeshttps://doi.org/10.1016/j.cps.2009.07.008openalex-snapshot
Systemic Therapy for Cutaneous Melanoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2006.11.007openalex-snapshot
Novel treatment strategies for malignant melanoma: A new beginning?
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2007.12.007openalex-snapshot
Dendritic cell vaccines in melanoma: From promise to proof?
inferred← citeshttps://doi.org/10.1016/j.ctrv.2006.07.009openalex-snapshot
Targeted therapies in melanoma
inferred← citeshttps://doi.org/10.1016/j.ctrv.2013.04.006openalex-snapshot
Immunotherapy for advanced melanoma: Fulfilling the promise
inferred← citeshttps://doi.org/10.1016/j.ctrv.2015.04.001openalex-snapshot
Addressing the unmet need in lung cancer: The potential of immuno-oncology
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2018.04.001openalex-snapshot
Gearing up T-cell immunotherapy in cervical cancer
inferred← citeshttps://doi.org/10.1016/j.cytogfr.2007.06.020openalex-snapshot
Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma
inferred← citeshttps://doi.org/10.1016/j.ddmec.2008.04.008openalex-snapshot
Targeted therapeutic strategies in malignant melanoma
inferred← citeshttps://doi.org/10.1016/j.ejca.2009.05.004openalex-snapshot
Therapeutic vaccines in solid tumours: Can they be harmful?
inferred← citeshttps://doi.org/10.1016/j.ejca.2013.06.027openalex-snapshot
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
inferred← citeshttps://doi.org/10.1016/j.ejca.2015.08.012openalex-snapshot
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
inferred← citeshttps://doi.org/10.1016/j.ejca.2015.11.016openalex-snapshot
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
inferred← citeshttps://doi.org/10.1016/j.ejca.2018.10.017openalex-snapshot
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.01.003openalex-snapshot
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
inferred← citeshttps://doi.org/10.1016/j.ejcsup.2013.07.013openalex-snapshot
Immunotherapy of melanoma
inferred← citeshttps://doi.org/10.1016/j.ejim.2017.08.019openalex-snapshot
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
inferred← citeshttps://doi.org/10.1016/j.humimm.2009.01.017openalex-snapshot
Melanoma vaccines: The problems of local immunosuppression
inferred← citeshttps://doi.org/10.1016/j.imlet.2007.11.012openalex-snapshot
Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer
inferred← citeshttps://doi.org/10.1016/j.imlet.2010.06.005openalex-snapshot
Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile
inferred← citeshttps://doi.org/10.1016/j.imlet.2016.11.009openalex-snapshot
Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4+CD25bri regulatory T cells
inferred← citeshttps://doi.org/10.1016/j.imlet.2019.12.010openalex-snapshot
Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity
inferred← citeshttps://doi.org/10.1016/j.immuni.2016.04.023openalex-snapshot
Targeting T Cell Co-receptors for Cancer Therapy
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.107703openalex-snapshot
Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.113952openalex-snapshot
Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity
inferred← citeshttps://doi.org/10.1016/j.jcma.2016.08.005openalex-snapshot
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment
inferred← citeshttps://doi.org/10.1016/j.jconrel.2018.09.009openalex-snapshot
Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity
inferred← citeshttps://doi.org/10.1016/j.jconrel.2020.11.056openalex-snapshot
Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine
inferred← citeshttps://doi.org/10.1016/j.jim.2008.01.012openalex-snapshot
Comparative methodologies of regulatory T cell depletion in a murine melanoma model
inferred← citeshttps://doi.org/10.1016/j.jtho.2023.04.020openalex-snapshot
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
inferred← citeshttps://doi.org/10.1016/j.mam.2013.10.003openalex-snapshot
Stem cells and targeted approaches to melanoma cure
inferred← citeshttps://doi.org/10.1016/j.medcle.2016.02.022openalex-snapshot
Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer
inferred← citeshttps://doi.org/10.1016/j.medcli.2015.02.010openalex-snapshot
Endocrinopatías autoinmunitarias inducidas por anticuerpos inmunomoduladores en el tratamiento del cáncer
inferred← citeshttps://doi.org/10.1016/j.molmed.2008.09.010openalex-snapshot
The complex role of B7 molecules in tumor immunology
inferred← citeshttps://doi.org/10.1016/j.msec.2018.12.017openalex-snapshot
Synthesis and characterization of a novel biocompatible pseudo-hexagonal NaCa-layered double metal hydroxides for smart pH-responsive drug release of dacarbazine and enhanced anticancer activity in malignant melanoma
inferred← citeshttps://doi.org/10.1016/j.oncohp.2016.01.002openalex-snapshot
Les anticorps monoclonaux dirigés contre les checkpoints immunologiques : de nouvelles approches d’immunothérapie en onco-hématologie
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2014.11.017openalex-snapshot
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2026.109124openalex-snapshot
Neuroregulation as a modulatory force in immune checkpoint inhibitor resistance: mechanistic neuro-immune crosstalk informing biomarker-led diagnosis and targetable therapeutic sensitization
inferred← citeshttps://doi.org/10.1016/j.prp.2024.155104openalex-snapshot
Immunotherapy for lung cancer
inferred← citeshttps://doi.org/10.1016/j.soc.2007.07.010openalex-snapshot
Current Immunotherapeutic Strategies in Malignant Melanoma
inferred← citeshttps://doi.org/10.1016/j.soc.2007.07.011openalex-snapshot
Cytokine Therapy for Cancer
inferred← citeshttps://doi.org/10.1016/j.soc.2007.12.003openalex-snapshot
Translational Research in Melanoma
inferred← citeshttps://doi.org/10.1016/j.soc.2010.09.004openalex-snapshot
Immunotherapy of Melanoma: An Update
inferred← citeshttps://doi.org/10.1016/j.suc.2017.01.014openalex-snapshot
Molecular Markers for Colorectal Cancer
inferred← citeshttps://doi.org/10.1016/j.tem.2021.10.009openalex-snapshot
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.tips.2013.11.004openalex-snapshot
Molecularly targeted cancer therapy: some lessons from the past decade
inferred← citeshttps://doi.org/10.1016/j.tips.2015.06.005openalex-snapshot
New immunotherapies targeting the PD-1 pathway
inferred← citeshttps://doi.org/10.1016/j.trecan.2019.07.006openalex-snapshot
Tissue Site and the Cancer Immunity Cycle
inferred← citeshttps://doi.org/10.1016/j.uct.2007.09.001openalex-snapshot
Anti-CTLA4 antibody clinical trials in melanoma
inferred← citeshttps://doi.org/10.1016/j.vaccine.2007.06.043openalex-snapshot
Enhancing cancer vaccines with immunomodulators
inferred← citeshttps://doi.org/10.1016/j.xinn.2024.100638openalex-snapshot
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma
inferred← citeshttps://doi.org/10.1016/s0001-4079(19)30188-8openalex-snapshot
Effets endocriniens et métaboliques des immunothérapies anticancéreuses (d’après les recommandations de la Société française d’endocrinologie)
inferred← citeshttps://doi.org/10.1016/s0065-230x(07)99006-5openalex-snapshot
Dendritic Cells in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/s0065-2776(06)90008-xopenalex-snapshot
Checkpoint Blockade in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/s0151-9638(07)91612-9openalex-snapshot
Lymphocytes T régulateurs
inferred← citeshttps://doi.org/10.1016/s1470-2045(15)00544-6openalex-snapshot
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
inferred← citeshttps://doi.org/10.1016/s1470-2045(17)30446-1openalex-snapshot
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
showing the first 200 of 574 · page through all 574
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.